Basel, MDPI, 2025.
Reports the positive impact of direct-acting antivirals on outcomes for people with hepatitis C. Highlights the need for ongoing monitoring for those at risk of liver cancer, screening for people at risk of infection or reinfection, ensuring safe medical procedures, needle and syringe provision and the need to continue working on the development of a vaccine.
London, Springer Nature, 2021.
Tremendous hope is placed on the ability of DAA therapy to bring about substantial improvements in life functioning after viral cure. Highly interconnected effects on quality of life worked synergistically through improved physical and psychological well-being. Stakeholders should appreciate the multi-dimensional benefits that viral eradication bestows upon individuals and society.
London, BioMed Central, 2018.
While cure is an obvious outcome of HCV treatment, patients are seeking change in other areas of their lives. This study also provides valuable insights for the development of patient-reported measures in this context, which would be an important step towards more patient-centred approaches to HCV treatment.
Melbourne, Gender Law and Drugs (GLaD), 2023.
Explores personal experiences of hep C in the era of new treatments and discusses social, policy and legal developments surrounding hep C in the new treatment era, including stigma and discrimination.
Melbourne, La Trobe University, 2023.
This 3 year, qualitative research project , undertaken between late 2020 and late 2023, sought to review laws, policies and practices that impact people affected by hep C in Australia, particularly after treatment.
For enquiries or feedback, please contact the librarian at Librarian@hepatitissa.asn.au.
| Address: | 3 Hackney Road Hackney SA 5069 |
| Phone: | (08) 8362 8443 |
| Fax: | (08) 8362 8559 |
| Email: | Librarian@hepatitissa.asn.au |
| Post: | PO Box 782 Kent Town SA 5071 |
Monday – Friday
9am to 5pm
Hepatitis SA is a non-profit, community-based organisation that provides information, education and support services to South Australians affected by hepatitis B and hepatitis C.